KUALA LUMPUR, Jan 7 -- Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and delivery of immune-based therapies, has announced the appointment of John Orloff, MD to its Board of Directors.
Dr Orloff joins the Zenas Board with over 25 years of experience successfully leading global research and development organisations across multiple therapeutic areas including autoimmune diseases.
“We are extremely pleased to welcome Dr Orloff to the Zenas Board of Directors,” said Lonnie Moulder, Founder and Executive Chairman of Zenas in a statement.
“John’s leadership and extensive expertise in research, development, and medical and regulatory affairs will be invaluable as we advance our portfolio of innovative immune-based therapeutics and continue to expand our pipeline via business development.”
Meanwhile, Dr Orloff said: “I am delighted to work with the Zenas leadership team and fellow directors as the Company rapidly progresses an exciting immune-based pipeline. I look forward to contributing to the Company’s continued development as it strives to deliver on its mission to bring innovative medicines to patients in need.”
He currently serves as a venture partner with Agent Capital. In his most recent executive role, he served as Executive Vice President and Head of Research and Development at Alexion where his leadership in expanding the development pipeline to 30 programs supported the recent US$39 billion acquisition of Alexion by AstraZeneca. (US$1 = RM4.213)
Before entering the biopharmaceutical industry, Dr Orloff was a faculty member of the Yale University School of Medicine.
He received an undergraduate degree in chemistry from Dartmouth College, earned his medical degree from the University of Vermont, College of Medicine and completed a fellowship in endocrinology and metabolism at Yale University School of Medicine.
For more information on Zenas BioPharma, visit www.zenasbio.com.
-- BERNAMA
No comments:
Post a Comment